AI Engines For more Details: Perplexity Kagi Labs You
Cerebral Blood Flow: Vinpocetine is believed to enhance cerebral blood flow by acting as a vasodilator and improving microcirculation in the brain. This increased blood flow may potentially enhance oxygen and nutrient delivery to brain cells, supporting cognitive function and overall brain health.
Neuroprotection: Vinpocetine has been studied for its potential neuroprotective effects, particularly in conditions associated with cerebral ischemia or reduced blood flow to the brain. It may help protect neurons from damage caused by ischemia, hypoxia, or neurotoxicity, thereby preserving cognitive function and reducing the risk of neurodegenerative diseases.
Cognitive Enhancement: Some studies suggest that vinpocetine may have cognitive-enhancing effects, including improvements in memory, attention, and executive function. These effects are thought to be mediated by its ability to enhance cerebral blood flow, increase glucose utilization in the brain, and modulate neurotransmitter activity.
Antioxidant Activity: Vinpocetine exhibits antioxidant properties, which may help reduce oxidative stress and inflammation in the brain. By scavenging free radicals and inhibiting oxidative damage to cellular components, vinpocetine may contribute to neuroprotection and cognitive health.
Anti-inflammatory Effects: Vinpocetine has been reported to possess anti-inflammatory properties, which could be beneficial in mitigating neuroinflammation and associated neurodegenerative processes. By suppressing inflammatory signaling pathways and cytokine production, vinpocetine may help protect against neuronal injury and cognitive decline.
Clinical Applications: Vinpocetine is used clinically in some countries for the treatment of cerebrovascular disorders, cognitive impairment, and age-related cognitive decline. It may also be prescribed as an adjunctive therapy in the management of conditions such as stroke, vascular dementia, and Alzheimer's disease.
Safety and Tolerability: Vinpocetine is generally well-tolerated when used at recommended doses. Common side effects may include gastrointestinal disturbances, headache, dizziness, and flushing. Rare adverse effects such as hypotension, arrhythmias, and allergic reactions have been reported with high doses or prolonged use.
Drug Interactions: Vinpocetine may interact with certain medications, particularly those affecting blood clotting or platelet function. Caution is advised when combining vinpocetine with anticoagulants, antiplatelet agents, or drugs that affect hemostasis to avoid the risk of bleeding or hemorrhage.
Regulatory Status: The regulatory status of vinpocetine varies by country. In some regions, it is available as a dietary supplement or over-the-counter medication, while in others, it is classified as a prescription drug. Consultation with a healthcare professional is recommended before initiating vinpocetine therapy to ensure appropriate use and monitoring.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Akkermansia muciniphila | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| species | Parabacteroides distasonis | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 1 | 1 | |
| Acne | 0.6 | 0.3 | 1 |
| ADHD | 4 | 0.6 | 5.67 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
| Allergic Rhinitis (Hay Fever) | 3.5 | 2 | 0.75 |
| Allergies | 6.9 | 2.9 | 1.38 |
| Allergy to milk products | 2.3 | 1.6 | 0.44 |
| Alopecia (Hair Loss) | 1 | 1 | |
| Alzheimer's disease | 6 | 6.3 | -0.05 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 3.8 | 1.3 | 1.92 |
| Ankylosing spondylitis | 3.8 | 1.6 | 1.37 |
| Anorexia Nervosa | 1.6 | 2.9 | -0.81 |
| Antiphospholipid syndrome (APS) | 1.9 | 0.3 | 5.33 |
| Asthma | 4.2 | 3.1 | 0.35 |
| Atherosclerosis | 2.1 | 2.4 | -0.14 |
| Atrial fibrillation | 4 | 2.5 | 0.6 |
| Autism | 8.7 | 9.1 | -0.05 |
| Autoimmune Disease | 1.2 | 1 | 0.2 |
| Barrett esophagus cancer | 0.3 | 0.3 | 0 |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 1.6 | 1.6 | |
| Bipolar Disorder | 2.1 | 1.4 | 0.5 |
| Brain Trauma | 0.9 | 1.4 | -0.56 |
| Breast Cancer | 0.4 | 0.4 | |
| Cancer (General) | 0.3 | 2.1 | -6 |
| Carcinoma | 3.5 | 2.3 | 0.52 |
| Celiac Disease | 3 | 3.6 | -0.2 |
| Cerebral Palsy | 1.8 | 1.3 | 0.38 |
| Chronic Fatigue Syndrome | 4 | 5.7 | -0.43 |
| Chronic Kidney Disease | 4.2 | 2.7 | 0.56 |
| Chronic Lyme | 0.6 | 0.8 | -0.33 |
| Chronic Obstructive Pulmonary Disease (COPD) | 1.3 | 1.7 | -0.31 |
| Chronic Urticaria (Hives) | 1.7 | 1.2 | 0.42 |
| Coagulation / Micro clot triggering bacteria | 1.7 | 1.3 | 0.31 |
| Cognitive Function | 3.6 | 1.3 | 1.77 |
| Colorectal Cancer | 6.6 | 2.5 | 1.64 |
| Constipation | 2.1 | 0.7 | 2 |
| Coronary artery disease | 2.8 | 2.7 | 0.04 |
| COVID-19 | 8.6 | 11.1 | -0.29 |
| Crohn's Disease | 8.1 | 6.1 | 0.33 |
| Cushing's Syndrome (hypercortisolism) | 0.9 | -0.9 | |
| cystic fibrosis | 0.9 | 1.6 | -0.78 |
| d-lactic acidosis (one form of brain fog) | 0.4 | 0.4 | |
| deep vein thrombosis | 3.2 | 1.4 | 1.29 |
| Denture Wearers Oral Shifts | 0.7 | 0.7 | |
| Depression | 9.2 | 9.7 | -0.05 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 2 | 1.8 | 0.11 |
| Endometriosis | 3.2 | 2.1 | 0.52 |
| Eosinophilic Esophagitis | 0.6 | -0.6 | |
| Epilepsy | 3.8 | 2.3 | 0.65 |
| erectile dysfunction | 1.8 | 0.3 | 5 |
| Fibromyalgia | 2.3 | 2.1 | 0.1 |
| Functional constipation / chronic idiopathic constipation | 5.8 | 3.6 | 0.61 |
| gallstone disease (gsd) | 4.1 | 1.3 | 2.15 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.5 | 1.2 | 0.25 |
| Generalized anxiety disorder | 3 | 2.6 | 0.15 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 1.8 | 1.2 | 0.5 |
| Graves' disease | 1.9 | 3.3 | -0.74 |
| Gulf War Syndrome | 0.9 | 2.6 | -1.89 |
| Halitosis | 0.9 | 0.3 | 2 |
| Hashimoto's thyroiditis | 3.4 | 1.6 | 1.13 |
| Heart Failure | 4.5 | 2.3 | 0.96 |
| hemorrhagic stroke | 1 | 1 | |
| Hidradenitis Suppurativa | 1.2 | 0.3 | 3 |
| High Histamine/low DAO | 1.7 | 0.6 | 1.83 |
| hypercholesterolemia (High Cholesterol) | 0.6 | 0.6 | 0 |
| hyperglycemia | 2 | 2.2 | -0.1 |
| Hyperlipidemia (High Blood Fats) | 1.3 | 0.3 | 3.33 |
| hypersomnia | 0.7 | -0.7 | |
| hypertension (High Blood Pressure | 4.7 | 5.2 | -0.11 |
| Hypothyroidism | 0.4 | 0.7 | -0.75 |
| Hypoxia | 3.8 | 0.3 | 11.67 |
| IgA nephropathy (IgAN) | 1.3 | 4.5 | -2.46 |
| Inflammatory Bowel Disease | 7.6 | 8.5 | -0.12 |
| Insomnia | 1.9 | 3.4 | -0.79 |
| Intelligence | 1.7 | 1.7 | |
| Intracranial aneurysms | 1.2 | 0.9 | 0.33 |
| Irritable Bowel Syndrome | 8.3 | 6.1 | 0.36 |
| ischemic stroke | 3.1 | 1.7 | 0.82 |
| Liver Cirrhosis | 6.6 | 5.3 | 0.25 |
| Long COVID | 6.8 | 7.5 | -0.1 |
| Low bone mineral density | 1.1 | -1.1 | |
| Lung Cancer | 1.4 | 1.6 | -0.14 |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 0.9 | 0.9 | 0 |
| ME/CFS with IBS | 0.6 | 2.4 | -3 |
| ME/CFS without IBS | 1.2 | 1.7 | -0.42 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 1.3 | 1 | 0.3 |
| Metabolic Syndrome | 7.9 | 7.7 | 0.03 |
| Mood Disorders | 9.3 | 7.9 | 0.18 |
| multiple chemical sensitivity [MCS] | 1.1 | 0.1 | 10 |
| Multiple Sclerosis | 6.3 | 5.6 | 0.13 |
| Multiple system atrophy (MSA) | 1 | 0.7 | 0.43 |
| myasthenia gravis | 0.9 | 0.7 | 0.29 |
| neuropathic pain | 2.3 | -2.3 | |
| Neuropathy (all types) | 0.8 | 2.2 | -1.75 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.6 | 0.6 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 4.3 | 5 | -0.16 |
| NonCeliac Gluten Sensitivity | 1.6 | 0.6 | 1.67 |
| Obesity | 9.5 | 7.7 | 0.23 |
| obsessive-compulsive disorder | 6 | 3.4 | 0.76 |
| Osteoarthritis | 2.8 | 1.6 | 0.75 |
| Osteoporosis | 2.2 | 1.9 | 0.16 |
| pancreatic cancer | 0.3 | 0.3 | 0 |
| Parkinson's Disease | 8.1 | 6.2 | 0.31 |
| Polycystic ovary syndrome | 6.1 | 2.9 | 1.1 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.6 | -2 |
| Premenstrual dysphoric disorder | 0.7 | 0.4 | 0.75 |
| primary biliary cholangitis | 1.2 | 1.4 | -0.17 |
| Primary sclerosing cholangitis | 1.9 | 2.7 | -0.42 |
| Psoriasis | 4 | 2.8 | 0.43 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 7.3 | 4.1 | 0.78 |
| Rosacea | 0.6 | 1 | -0.67 |
| Schizophrenia | 6.2 | 3.5 | 0.77 |
| scoliosis | 0.6 | 1 | -0.67 |
| Sjögren syndrome | 2.1 | 2.9 | -0.38 |
| Sleep Apnea | 1.9 | 1.6 | 0.19 |
| Slow gastric motility / Gastroparesis | 1.2 | 0.3 | 3 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.7 | 0.3 | 4.67 |
| Stress / posttraumatic stress disorder | 3.1 | 2.7 | 0.15 |
| Systemic Lupus Erythematosus | 4.1 | 1.6 | 1.56 |
| Tic Disorder | 1.2 | 1.2 | 0 |
| Tourette syndrome | 1.3 | 0.3 | 3.33 |
| Type 1 Diabetes | 4.9 | 3.8 | 0.29 |
| Type 2 Diabetes | 8.7 | 8.8 | -0.01 |
| Ulcerative colitis | 5.5 | 7.1 | -0.29 |
| Unhealthy Ageing | 4.6 | 2.6 | 0.77 |
| Vitiligo | 2.5 | 2 | 0.25 |
